Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
#3PRI RANKED
Most Cited Paper
in Pancreatic function and diabetes
18 Months Post-Publication
Class of 2026
“Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/pancreatic-function-and-diabetes/2026/
Topics
semaglutide · SGLT2 inhibitors · Type 2 diabetes · chronic kidney disease · FLOW trial · GLP-1 receptor agonists · kidney failure · Estimated glomerular filtration rate · cardiovascular death · Cardiovascular events · All-cause mortality · combination therapy · kidney outcomes · eGFR slope · Hazard ratio
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Pancreatic function and diabetes Papers, Class of 2026. https://pri.pepkio.com/top-papers/pancreatic-function-and-diabetes/2026. Accessed 2026-07-21. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459